Mylan tops profit estimates as newer drugs spur North America growth

Mylan NV beat Wall Street estimates for third-quarter profit on Tuesday, as its biggest market, North America, benefited from launches of lung disease therapies Wixela and Yupelri.

…read more

Source:: Reuters – Business News

      

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.